12/02/2015 - 3:45pm

According to an Associated Press report published in the New York Times, a bipartisan Senate Finance committee report found that Gilead Sciences, maker of hepatitis C treatments Harvoni and Sovaldi, chose to price Sovaldi at $1,000 a pill ($84,000 for a course of treatment) despite evidence that a lower price would allow more people to take advantage of the treatment. Gilead rejected the committee’s conclusions, noting that it “responsibly and thoughtfully priced Sovaldi and Harvoni,” as lawmakers point to this case as a cautionary tale for other expensive treatments. (New York Times)

12/02/2015 - 11:10am

The Detroit Free Press Top Workplaces are based solely on employee feedback. In Michigan this year, more than 61,000 employees filled out surveys.  

11/30/2015 - 12:54pm

Takeda’s Ninlaro is a treatment for patients with multiple myeloma who have had at least one prior therapy. 

11/30/2015 - 10:29am

The combined company’s revenue for the 12 months ended June 30 exceeded $800 million. 

11/24/2015 - 1:31pm

Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months. 

11/20/2015 - 3:55pm

Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.

11/20/2015 - 9:29am

The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted. 

11/19/2015 - 1:37pm

The healthcare logistics industry has seen significant improvements in product security and regulatory compliance across the supply chain. 

11/18/2015 - 11:49am

AxelaCare enhances OptumRx’s ability to deliver care to the growing number of consumers managing complex conditions through at-home infusions.